Hypoxia-inducible factors - regulation, role and comparative aspects in tumourigenesis

Veterinary and Comparative Oncology

Volumn 9, Issue 1, 2011, Pages 16-37

  Hansen, A E ^a   Kristensen, A T ^a   Law, I ^b   Jorgensen J T ^c   Engelholm, S A ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d FINSEN LABORATORY   (Denmark)

Author keywords

Comparative animal models; HIF; Hypoxia; Translational models; Tumour microenvironment

Indexed keywords

BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1; MICRORNA;

ANIMAL; ANIMAL DISEASE; CANCER STEM CELL; CAT; CAT DISEASE; CELL HYPOXIA; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; DOG; DOG DISEASE; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CAT DISEASES; CATS; CELL HYPOXIA; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; HYPOXIA-INDUCIBLE FACTOR 1; MICRORNAS; NEOPLASMS; NEOPLASTIC STEM CELLS;

ANIMALIA;

EID: 79551693230     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00233.x     Document Type: Review

References (190)

1. Vaupel P and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Reviews 2007; 26: 225-239.
2. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9(Suppl. 5): 10-17.
3. Vaupel P, Thews O and Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Medical Oncology 2001; 18: 243-259.
4. Fukumura D and Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. Journal of Cellular Biochemistry 2007; 101: 937-949.
5. Brahimi-Horn C and Pouyssegur J. The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bulletin du Cancer 2006; 93: E73-E80.
6. Axelson H, Fredlund E, Ovenberger M, Landberg G and Pahlman S. Hypoxia-induced dedifferentiation of tumor cells - a mechanism behind heterogeneity and aggressiveness of solid tumors. Seminars in Cell & Developmental Biology 2005; 16: 554-563.
7. Alqawi O, Wang HP, Espiritu M and Singh G. Chronic hypoxia promotes an aggressive phenotype in rat prostate cancer cells. Free Radical Research 2007; 41: 788-797.
8. Bristow RG and Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nature Reviews Cancer 2008; 8: 180-192.
9. Gu YZ, Moran SM, Hogenesch JB, Wartman L and Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expression 1998; 7: 205-213.
10. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH and Eckardt KU. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. The FASEB Journal 2003; 17: 271-273.
11. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annual Review of Cell and Developmental Biology 1999; 15: 551-578.
12. Ota K, Nagai H and Sheng G. Expression and hypoxic regulation of hif1alpha and hif2alpha during early blood and endothelial cell differentiation in chick. Gene Expression Patterns 2007; 7: 761-766.
13. Khatua S, Peterson KM, Brown KM, Lawlor C, Santi MR, LaFleur B, Dressman D, Stephan DA and MacDonald TJ. Overexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profiling. Cancer Research 2003; 63: 1865-1870.
14. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, Gatter KC and Harris AL. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics 2002; 53: 1192-1202.
15. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Science's STKE 2007; 2007: cm8.
16. Takahata S, Sogawa K, Kobayashi A, Ema M, Mimura J, Ozaki N and Fujii-Kuriyama Y. Transcriptionally active heterodimer formation of an Arnt-like PAS protein, Arnt3, with HIF-1a, HLF, and clock. Biochemical and Biophysical Research Communications 1998; 248: 789-794.
17. Hirose K, Morita M, Ema M, Mimura J, Hamada H, Fujii H, Saijo Y, Gotoh O, Sogawa K and Fujii-Kuriyama Y. cDNA cloning and tissue-specific expression of a novel basic helix-loop-helix/PAS factor (Arnt2) with close sequence similarity to the aryl hydrocarbon receptor nuclear translocator (Arnt). Molecular and Cellular Biology 1996; 16: 1706-1713.
18. Semenza GL. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003; 3: 721-732.
19. Michel G, Minet E, Ernest I, Roland I, Durant F, Remacle J and Michiels C. A model for the complex between the hypoxia-inducible factor-1 (HIF-1) and its consensus DNA sequence. Journal of Biomolecular Structure & Dynamics 2000; 18: 169-179.
20. Bracken CP, Whitelaw ML and Peet DJ. The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses. Cellular and Molecular Life Sciences 2003; 60: 1376-1393.
21. Carrero P, Okamoto K, Coumailleau P, O'Brien S, Tanaka H and Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Molecular and Cellular Biology 2000; 20: 402-415.
22. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L and Fujii-Kuriyama Y. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. The EMBO Journal 1999; 18: 1905-1914.
23. Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J and Mazure NM. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Research 2006; 66: 3688-3698.
24. 2 tension. The American Journal of Physiology 1996; 271(4 Pt 1): C1172-C1180.
25. Hu CJ, Sataur A, Wang L, Chen H and Simon MC. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha. Molecular Biology of the Cell 2007; 18: 4528-4542.
26. Hu CJ, Iyer S, Sataur A, Covello KL, Chodosh LA and Simon MC. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Molecular and Cellular Biology 2006; 26: 3514-3526.
27. Belozerov VE and Van Meir EG. Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs 2005; 16: 901-909.
28. Lofstedt T, Fredlund E, Holmquist-Mengelbier L, Pietras A, Ovenberger M, Poellinger L and Pahlman S. Hypoxia inducible factor-2alpha in cancer. Cell Cycle 2007; 6: 919-926.
29. Heidbreder M, Frohlich F, Johren O, Dendorfer A, Qadri F and Dominiak P. Hypoxia rapidly activates HIF-3alpha mRNA expression. The FASEB Journal 2003; 17: 1541-1543.
30. Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A and Poellinger L. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001; 414: 550-554.
31. Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC and Harris AL. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology 2005; 47: 602-610.
32. Koivunen P, Tiainen P, Hyvarinen J, Williams KE, Sormunen R, Klaus SJ, Kivirikko KI and Myllyharju J. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. The Journal of Biological Chemistry 2007; 282: 30544-30552.
33. Mole DR, Maxwell PH, Pugh CW and Ratcliffe PJ. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life 2001; 52: 43-47.
34. Berra E, Benizri E, Ginouves A, Volmat V, Roux D and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. The EMBO Journal 2003; 22: 4082-4090.
35. Schofield CJ and Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochemical and Biophysical Research Communications 2005; 338: 617-626.
36. Baek JH, Liu YV, McDonald KR, Wesley JB, Zhang H and Semenza GL. Spermidine/spermine N(1)-acetyltransferase-1 binds to hypoxia-inducible factor-1alpha (HIF-1alpha) and RACK1 and promotes ubiquitination and degradation of HIF-1alpha. The Journal of Biological Chemistry 2007; 282: 33358-33366.
37. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 7987-7992.
38. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI and Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. The Journal of Biological Chemistry 2003; 278: 30772-30780.
39. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ and Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. The Journal of Biological Chemistry 2004; 279: 38458-38465.
40. Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, Jelkmann W, Jaakkola P and Metzen E. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. The Biochemical Journal 2004; 381(Pt 3): 761-767.
41. Metzen E and Ratcliffe PJ. HIF hydroxylation and cellular oxygen sensing. Biological Chemistry 2004; 385: 223-230.
42. Takeda K, Aguila HL, Parikh NS, Li X, Lamothe K, Duan LJ, Takeda H, Lee FS and Fong GH. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008; 111: 3229-3235.
43. Takeda K, Cowan A and Fong GH. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 2007; 116: 774-781.
44. Fong GH and Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death and Differentiation 2008; 15: 635-641.
45. Stiehl DP, Wirthner R, Koditz J, Spielmann P, Camenisch G and Wenger RH. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. The Journal of Biological Chemistry 2006; 281: 23482-23491.
46. Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, Kadoya T, Erdjument-Bromage H, Tempst P, Frappell PB, Bowtell DD and Ronai Z. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 2004; 117: 941-952.
47. Qi J, Nakayama K, Gaitonde S, Goydos JS, Krajewski S, Eroshkin A, Bar-Sagi D, Bowtell D and Ronai Z. The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 16713-16718.
48. Barth S, Nesper J, Hasgall PA, Wirthner R, Nytko KJ, Edlich F, Katschinski DM, Stiehl DP, Wenger RH and Camenisch G. The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Molecular and Cellular Biology 2007; 27: 3758-3768.
49. Rosner M, Hofer K, Kubista M and Hengstschlager M. Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38. Oncogene 2003; 22: 4786-4798.
50. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC and Chandel NS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metabolism 2005; 1: 409-414.
51. Hagen T, Taylor CT, Lam F and Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003; 302: 1975-1978.
52. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U and Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metabolism 2005; 1: 401-408.
53. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT and Simon MC. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metabolism 2005; 1: 393-399.
54. Koivunen P, Hirsila M, Remes AM, Hassinen IE, Kivirikko KI and Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. The Journal of Biological Chemistry 2007; 282: 4524-4532.
55. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005; 7: 77-85.
56. Hewitson KS, Lienard BM, McDonough MA, Clifton IJ, Butler D, Soares AS, Oldham NJ, McNeill LA and Schofield CJ. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. The Journal of Biological Chemistry 2007; 282: 3293-3301.
57. Baek JH, Mahon PC, Oh J, Kelly B, Krishnamachary B, Pearson M, Chan DA, Giaccia AJ and Semenza GL. OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Molecular Cell 2005; 17: 503-512.
58. Vourvouhaki E, Carvalho C and Aguiar P. Model for Osteosarcoma-9 as a potent factor in cell survival and resistance to apoptosis. Physical Review E, Statistical, Nonlinear, and Soft Matter Physics 2007; 76(1 Pt 1): 011926.
59. Bae SH, Jeong JW, Park JA, Kim SH, Bae MK, Choi SJ and Kim KW. Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochemical and Biophysical Research Communications 2004; 324: 394-400.
60. Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F and Arzt E. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 2007; 131: 309-323.
61. Berta MA, Mazure N, Hattab M, Pouyssegur J and Brahimi-Horn MC. SUMOylation of hypoxia-inducible factor-1alpha reduces its transcriptional activity. Biochemical and Biophysical Research Communications 2007; 360: 646-652.
62. Cheng J, Kang X, Zhang S and Yeh ET. SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. Cell 2007; 131: 584-595.
63. Liu YV, Baek JH, Zhang H, Diez R, Cole RN and Semenza GL. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Molecular Cell 2007; 25: 207-217.
64. Baek JH, Liu YV, McDonald KR, Wesley JB, Hubbi ME, Byun H and Semenza GL. Spermidine/spermine-N1-acetyltransferase 2 is an essential component of the ubiquitin ligase complex that regulates hypoxia-inducible factor 1alpha. The Journal of Biological Chemistry 2007; 282: 23572-23580.
65. Hewitson KS, McNeill LA, Elkins JM and Schofield CJ. The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans 2003; 31(Pt 3): 510-515.
66. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML and Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes & Development 2002; 16: 1466-1471.
67. Lando D, Peet DJ, Whelan DA, Gorman JJ and Whitelaw ML. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002; 295: 858-861.
68. Bracken CP, Fedele AO, Linke S, Balrak W, Lisy K, Whitelaw ML and Peet DJ. Cell-specific regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha stabilization and transactivation in a graded oxygen environment. The Journal of Biological Chemistry 2006; 281: 22575-22585.
69. Freedman SJ, Sun ZY, Kung AL, France DS, Wagner G and Eck MJ. Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nature Structural Biology 2003; 10: 504-512.
70. Aprelikova O, Wood M, Tackett S, Chandramouli GV and Barrett JC. Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Research 2006; 66: 5641-5647.
71. Wang V, Davis DA, Haque M, Huang LE and Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Research 2005; 65: 3299-3306.
72. Dewhirst MW, Cao Y and Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nature Reviews Cancer 2008; 8: 425-437.
73. Blancher C, Moore JW, Robertson N and Harris AL. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Research 2001; 61: 7349-7355.
74. Chan DA, Sutphin PD, Denko NC and Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. The Journal of Biological Chemistry 2002; 277: 40112-40117.
75. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM and Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. The Journal of Biological Chemistry 2002; 277: 38205-38211.
76. Jiang BH, Agani F, Passaniti A and Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Research 1997; 57: 5328-5335.
77. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Molecular and Cellular Biology 2001; 21: 3995-4004.
78. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes & Development 2000; 14: 34-44.
79. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D and Giaccia AJ. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes & Development 2000; 14: 391-396.
80. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ and Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Molecular and Cellular Biology 2002; 22: 7004-7014.
81. Jiang BH and Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resistance Updates 2008; 11: 63-76.
82. Reiling JH and Sabatini DM. Stress and mTORture signaling. Oncogene 2006; 25: 6373-6383.
83. Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, Dor Y, Zisman P and Meyuhas O. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes & Development 2005; 19: 2199-2211.
84. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J and Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature Medicine 2006; 12: 122-127.
85. Yee Koh M, Spivak-Kroizman TR and Powis G. HIF-1 regulation: not so easy come, easy go. Trends in Biochemical Sciences 2008; 33: 526-534.
86. Jiang BH and Liu LZ. AKT signaling in regulating angiogenesis. Current Cancer Drug Targets 2008; 8: 19-26.
87. Franovic A, Holterman CE, Payette J and Lee S. Human cancers converge at the HIF-2{alpha} oncogenic axis. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 21306-21311.
88. Engelman JA, Luo J and Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics 2006; 7: 606-619.
89. Guertin DA and Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9-22.
90. Hay N and Sonenberg N. Upstream and downstream of mTOR. Genes & Development 2004; 18: 1926-1945.
91. Huang J and Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochemical Society Transactions 2009; 37(Pt 1): 217-222.
92. Toschi A, Lee E, Gadir N, Ohh M and Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. The Journal of Biological Chemistry 2008; 283: 34495-34499.
93. Fumarola C, La Monica S, Alfieri RR, Borra E and Guidotti GG. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis. Cell Death and Differentiation 2005; 12: 1344-1357.
94. Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI and Grupp SA. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 2006; 107: 1149-1155.
95. Koumenis C and Wouters BG. "Translating" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Molecular Cancer Research 2006; 4: 423-436.
96. Liu L, Cash TP, Jones RG, Keith B, Thompson CB and Simon MC. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Molecular Cell 2006; 21: 521-531.
97. Harding HP, Zhang Y and Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999; 397: 271-274.
98. Wouters BG and Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nature Reviews Cancer 2008; 8: 851-864.
99. Koritzinsky M, Magagnin MG, van den Beucken T, Seigneuric R, Savelkouls K, Dostie J, Pyronnet S, Kaufman RJ, Weppler SA, Voncken JW, Lambin P, Koumenis C, Sonenberg N and Wouters BG. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. The EMBO Journal 2006; 25: 1114-1125.
100. Lang KJ, Kappel A and Goodall GJ. Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Molecular Biology of the Cell 2002; 13: 1792-1801.
101. Zhou J, Callapina M, Goodall GJ and Brune B. Functional integrity of nuclear factor kappaB, phosphatidylinositol 3'-kinase, and mitogen-activated protein kinase signaling allows tumor necrosis factor alpha-evoked Bcl-2 expression to provoke internal ribosome entry site-dependent translation of hypoxia-inducible factor 1alpha. Cancer Research 2004; 64: 9041-9048.
102. Young RM, Wang SJ, Gordan JD, Ji X, Liebhaber SA and Simon MC. Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism. The Journal of Biological Chemistry 2008; 283: 16309-16319.
103. Bert AG, Grepin R, Vadas MA and Goodall GJ. Assessing IRES activity in the HIF-1alpha and other cellular 5' UTRs. RNA 2006; 12: 1074-1083.
104. Richard DE, Berra E, Gothie E, Roux D and Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. The Journal of Biological Chemistry 1999; 274: 32631-32637.
105. Galanis A, Pappa A, Giannakakis A, Lanitis E, Dangaj D and Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Letters 2008; 266: 12-20.
106. Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V and Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. The Journal of Biological Chemistry 2003; 278: 14013-14019.
107. Emerling BM, Weinberg F, Liu JL, Mak TW and Chandel NS. PTEN regulates p300-dependent hypoxia-inducible factor 1 transcriptional activity through Forkhead transcription factor 3a (FOXO3a). Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 2622-2627.
108. Tang TT and Lasky LA. The forkhead transcription factor FOXO4 induces the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-independent mechanism. The Journal of Biological Chemistry 2003; 278: 30125-30135.
109. Hickey MM and Simon MC. Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Current Topics in Developmental Biology 2006; 76: 217-257.
110. Ma J, Zhang L, Ru GQ, Zhao ZS and Xu WJ. Upregulation of hypoxia inducible factor 1alpha mRNA is associated with elevated vascular endothelial growth factor expression and excessive angiogenesis and predicts a poor prognosis in gastric carcinoma. World Journal of Gastroenterology 2007; 13: 1680-1686.
111. Bergers G and Benjamin LE. Tumorigenesis and the angiogenic switch. Nature Reviews Cancer 2003; 3: 401-410.
112. Carroll VA and Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Research 2006; 66: 6264-6270.
113. Acker T, Diez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L, Fukumura D, Moreno-Murciano MP, Herbert JM, Burger A, Riedel J, Elvert G, Flamme I, Maxwell PH, Collen D, Dewerchin M, Jain RK, Plate KH and Carmeliet P. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 2005; 8: 131-141.
114. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008; 13(Suppl. 3): 21-26.
115. Gordan JD, Thompson CB and Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12: 108-113.
116. Gordan JD, Bertout JA, Hu CJ, Diehl JA and Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11: 335-347.
117. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC and Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. The EMBO Journal 2004; 23: 1949-1956.
118. Huang L, Ao Q, Zhang Q, Yang X, Xing H, Li F, Chen G, Zhou J, Wang S, Xu G, Meng L, Lu Y and Ma D. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. Journal of Cancer Research and Clinical Oncology 2009.
119. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P and Korsmeyer SJ. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. The Journal of Biological Chemistry 1999; 274: 1156-1163.
120. Kilic M, Kasperczyk H, Fulda S and Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 2007; 26: 2027-2038.
121. Sowter HM, Ratcliffe PJ, Watson P, Greenberg AH and Harris AL. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Research 2001; 61: 6669-6673.
122. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J and Mazure NM. Hypoxia-induced Autophagy is mediated through HIF-induction of BNIP3 and BNIP3L via their BH3-domains. Molecular and Cellular Biology 2009; 29: 2570-258129: 2570-2581.
123. Mellor HR and Harris AL. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Reviews 2007; 26: 553-566.
124. Chiche J, Rouleau M, Gounon P, Brahimi-Horn MC, Pouyssegur J and Mazure NM. Hypoxic enlarged mitochondria protect cancer cells from apoptotic stimuli. Journal of Cellular Physiology 222: 648-657.
125. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL and Ratcliffe PJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Molecular and Cellular Biology 2005; 25: 5675-5686.
126. Chen D, Li M, Luo J and Gu W. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. The Journal of Biological Chemistry 2003; 278: 13595-13598.
127. Hansson LO, Friedler A, Freund S, Rudiger S and Fersht AR. Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 10305-10309.
128. Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W, Lu Y, Zhao F, Wang L and Zhou Q. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. The Journal of Biological Chemistry 2009; 284: 10004-10012.
129. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M and Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. The Journal of Biological Chemistry 2006; 281: 25903-25914.
130. Piret JP, Minet E, Cosse JP, Ninane N, Debacq C, Raes M and Michiels C. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. The Journal of Biological Chemistry 2005; 280: 9336-9344.
131. Cardone RA, Casavola V and Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nature Reviews Cancer 2005; 5: 786-795.
132. Sullivan R and Graham CH. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Reviews 2007; 26: 319-331.
133. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939.
134. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC and Wu KJ. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nature Cell Biology 2008; 10: 295-305.
135. Gort EH, van Haaften G, Verlaan I, Groot AJ, Plasterk RH, Shvarts A, Suijkerbuijk KP, van Laar T, van der Wall E, Raman V, van Diest PJ, Tijsterman M and Vooijs M. The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene 2008; 27: 1501-1510.
136. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS and Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440: 1222-1226.
137. Erler JT and Giaccia AJ. Lysyl oxidase mediates hypoxic control of metastasis. Cancer Research 2006; 66: 10238-10241.
138. Pouyssegur J, Dayan F and Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441: 437-443.
139. Chan DA and Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Reviews 2007; 26: 333-339.
140. Petrella BL, Lohi J and Brinckerhoff CE. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 2005; 24: 1043-1052.
141. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology 2000; 2: 76-83.
142. Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, Raval R, O'Brien TS, Maxwell PH. Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Research 2006; 66: 3567-3575.
143. Esser S, Lampugnani MG, Corada M, Dejana E and Risau W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. Journal of Cell Science 1998; 111(Pt 13): 1853-1865.
144. Kevil CG, Payne DK, Mire E and Alexander JS. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. The Journal of Biological Chemistry 1998; 273: 15099-15103.
145. Liotta LA, Kleinerman J and Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Research 1974; 34: 997-1004.
146. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
147. DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabolism 2008; 7: 11-20.
148. Hsu PP and Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
149. Chen C, Pore N, Behrooz A, Ismail-Beigi F and Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. The Journal of Biological Chemistry 2001; 276: 9519-9525.
150. Gleadle JM and Ratcliffe PJ. Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 1997; 89: 503-509.
151. Mathupala SP, Rempel A and Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. The Journal of Biological Chemistry 2001; 276: 43407-43412.
152. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Reviews Cancer 2008.
153. Firth JD, Ebert BL and Ratcliffe PJ. Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. The Journal of Biological Chemistry 1995; 270: 21021-21027.
154. Ullah MS, Davies AJ and Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. The Journal of Biological Chemistry 2006; 281: 9030-9037.
155. Papandreou I, Cairns RA, Fontana L, Lim AL and Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism 2006; 3: 187-197.
156. Simon MC. Mitochondrial reactive oxygen species are required for hypoxic HIF alpha stabilization. Advances in Experimental Medicine and Biology 2006; 588: 165-170.
157. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV and Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007; 129: 111-122.
158. Ivanov S, Liao SY, Ivanova A, Danilkovitch- Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI and Stanbridge EJ. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. American Journal of Pathology 2001; 158: 905-919.
159. Grabmaier K, AdW MC, Verhaegh GW, Schalken JA and Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004; 23: 5624-5631.
160. Kaluz S, Kaluzova M, Liao SY, Lerman M and Stanbridge EJ. Transcriptional control of the tumor-and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show?. Biochimica et Biophysica Acta 2009; 1795: 162-172.
161. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nister M, Reifenberger G, Lundeberg J, Frisen J and Acker T. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133(Pt 4): 983-995.
162. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB and Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8: 3274-3284.
163. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB and Rich JN. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
164. Li Z, Wang H, Eyler CE, Hjelmeland AB and Rich JN. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. The Journal of Biological Chemistry 2009; 284: 16705-16709.
165. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD and Rich JN. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Research 2006; 66: 7843-7848.
166. Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H and Pahlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 7021-7026.
167. Mazumdar J, Dondeti V and Simon MC. Hypoxia-inducible factors in stem cells and cancer. Journal of Cellular and Molecular Medicine 2009; 13: 4319-4328.
168. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF and Park DM. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 2009; 28: 3949-3959.
169. Chambers I and Tomlinson SR. The transcriptional foundation of pluripotency. Development 2009; 136: 2311-2322.
170. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL and Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458: 780-783.
171. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB and Rich JN. Hypoxia inducible factors in cancer stem cells. British Journal of Cancer 102: 789-795.
172. Croce CM and Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122: 6-7.
173. Seila AC and Sharp PA. Small RNAs tell big stories in Whistler. Nature Cell Biology 2008; 10: 630-633.
174. Huang X.Le QT and Giaccia AJ. MiR-210 - micromanager of the hypoxia pathway. Trends in Molecular Medicine 2010; 16: 230-237.
175. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT and Giaccia AJ. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Molecular Cell 2009; 35: 856-867.
176. Giannakakis A, Sandaltzopoulos R, Greshock J, Liang S, Huang J, Hasegawa K, Li C, O'Brien-Jenkins A, Katsaros D, Weber BL, Simon C, Coukos G and Zhang L. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biology & Therapy 2008; 7: 255-264.
177. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QTand Koong AC. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Translational Oncology 3: 109-113.
178. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM and Ragoussis J. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clinical Cancer Research 2008; 14: 1340-1348.
179. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL, Frazier ML, Killary AM and Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prevention Research (Philadelphia Pa) 2009; 2: 807-813.
180. Paoloni M and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer 2008; 8: 147-156.
181. Achermann R, Ohlerth S, Fidel J, Gardelle O, Gassmann M, Roos M, Saunders HM, Scheid A, Wergin M and Kaser-Hotz B. Ultrasound guided, pre-radiation oxygen measurements using polarographic oxygen needle electrodes in spontaneous canine soft tissue sarcomas. In Vivo 2002; 16: 431-437.
182. Bruehlmeier M, Kaser-Hotz B, Achermann R, Bley CR, Wergin M, Schubiger PA and Ametamey SM. Measurement of tumor hypoxia in spontaneous canine sarcomas. Veterinary Radiology & Ultrasound 2005; 46: 348-354.
183. Kleiter MM, Thrall DE, Malarkey DE, Ji X, Lee DY, Chou SC and Raleigh JA. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. International Journal of Radiation Oncology, Biology, Physics 2006; 64: 592-602.
184. Jain RK, Tong RT and Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Research 2007; 67: 2729-2735.
185. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA and Johnson RS. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008; 456: 814-818.
186. Zhang Q, Bellotto DJ, Ravikumar P, Moe OW, Hogg RT, Hogg DC, Estrera AS, Johnson RL Jr. and Hsia CC. Postpneumonectomy lung expansion elicits hypoxia-inducible factor-1alpha signaling. American Journal of Physiology - Lung Cellular and Molecular Physiology 2007; 293: L497-504.
187. Zhang Q, Moe OW, Garcia JA and Hsia CC. Regulated expression of hypoxia-inducible factors during postnatal and postpneumonectomy lung growth. American Journal of Physiology - Lung Cellular and Molecular Physiology 2006; 290: L880-889.
188. Millanta F, Caneschi V, Ressel L, Citi S and Poli A. Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma. Journal of Comparative Pathology 142: 36-42.
189. Petty JC, Lana SE, Thamm DH, Charles JB, Bachand AM, Bush JM and Ehrhart EJ. Glucose transporter 1 expression in canine osteosarcoma. Veterinary and Comparative Oncology 2008; 6: 133-140.
190. Qiu CW, Lin DG, Wang JQ, Li CY and Deng GZ. Expression and significance of PTEN and VEGF in canine mammary gland tumours. Veterinary Research Communications 2008; 32: 463-472.